Dicerna Pharmaceuticals (NASDAQ:DRNA)‘s stock had its “hold” rating reiterated by HC Wainwright in a report released on Tuesday. They currently have a $14.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 1.74% from the stock’s previous close.
DRNA has been the subject of several other reports. BidaskClub upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, May 4th. Evercore ISI began coverage on Dicerna Pharmaceuticals in a report on Tuesday, January 16th. They set an “outperform” rating and a $14.00 price target for the company. Stifel Nicolaus raised their price target on Dicerna Pharmaceuticals from $10.00 to $17.00 and gave the company a “buy” rating in a report on Friday, March 9th. Zacks Investment Research downgraded Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 9th. Finally, Chardan Capital restated a “neutral” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $12.88.
Get Dicerna Pharmaceuticals alerts:
Dicerna Pharmaceuticals opened at $13.76 on Tuesday, according to Marketbeat Ratings. Dicerna Pharmaceuticals has a 12-month low of $13.09 and a 12-month high of $13.70.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its quarterly earnings data on Monday, May 14th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.57. The business had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.75 million. Dicerna Pharmaceuticals had a negative return on equity of 123.72% and a negative net margin of 1,665.11%. analysts predict that Dicerna Pharmaceuticals will post -1.56 EPS for the current fiscal year.
In other news, insider James B. Weissman sold 8,965 shares of the firm’s stock in a transaction on Friday, April 20th. The stock was sold at an average price of $13.00, for a total transaction of $116,545.00. Following the completion of the transaction, the insider now directly owns 9,800 shares in the company, valued at $127,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James B. Weissman sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 9th. The shares were sold at an average price of $15.00, for a total value of $150,000.00. Following the transaction, the insider now owns 19,800 shares of the company’s stock, valued at $297,000. The disclosure for this sale can be found here. Insiders have sold 20,000 shares of company stock valued at $280,000 over the last 90 days. Corporate insiders own 19.85% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DRNA. RTW Investments LP increased its holdings in Dicerna Pharmaceuticals by 142.2% in the 4th quarter. RTW Investments LP now owns 5,035,662 shares of the biopharmaceutical company’s stock worth $44,142,000 after buying an additional 2,956,671 shares in the last quarter. Bridger Management LLC bought a new stake in Dicerna Pharmaceuticals in the 4th quarter worth about $8,181,000. First Manhattan Co. bought a new stake in Dicerna Pharmaceuticals in the 4th quarter worth about $3,865,000. Artal Group S.A. bought a new stake in Dicerna Pharmaceuticals in the 1st quarter worth about $4,063,000. Finally, Millennium Management LLC increased its holdings in Dicerna Pharmaceuticals by 509.1% in the 1st quarter. Millennium Management LLC now owns 407,530 shares of the biopharmaceutical company’s stock worth $3,896,000 after buying an additional 340,623 shares in the last quarter. Institutional investors own 74.45% of the company’s stock.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.